Adagio Medical Holdings, INC

Adagio Medical Holdings, Inc. provided an updated corporate presentation detailing advancements in its Ultra Low Temperature Cryoablation (ULTA) technology for Ventricular Tachycardia (VT) ablation, with key regulatory milestones and product launches on the horizon.

Adagio Medical Holdings announced second quarter 2026 financial results, highlighting progress in its vCLAS Ultra catheter and FULCRUM-VT trial, alongside an increased net loss.

Adagio Medical Holdings, Inc. successfully concluded its 2026 Annual Meeting with the election of two directors and the ratification of its independent auditor.

Adagio Medical Holdings, Inc. has been notified by Nasdaq of non-compliance with the minimum $1.00 bid price requirement.

Adagio Medical Holdings, Inc. has submitted a Premarket Approval (PMA) application to the FDA for its vCLAS Ventricular Ablation System, a purpose-built solution for treating ventricular tachycardia.

Adagio Medical announced first quarter 2026 financial results and significant clinical advancements for its Ultra-Low Temperature Ablation (ULTA) technology, particularly for ventricular tachycardia.

Adagio Medical Holdings, Inc. reported continued net losses and significant cash burn in its Q2 2026 10-Q filing, raising substantial doubt about its ability to continue as a going concern, despite advancing its vCLAS Ventricular Ablation System through clinical trials and regulatory submissions.

Adagio Medical Holdings, Inc. reported reduced net losses for the first quarter of 2026 compared to the prior year, driven by decreased operating expenses, though the company continues to face substantial going concern risks.

Adagio Medical Holdings, Inc. reported a significant net loss for Q3 2025, alongside a recent $19 million private placement and progress in its FULCRUM-VT clinical trial.

Adagio Medical Holdings, Inc. reported no revenue for Q2 2025 and expressed substantial doubt about its ability to continue as a going concern, despite receiving FDA Breakthrough Device designation.

Adagio Medical Holdings reports a net loss for Q1 2025 while prioritizing its FULCRUM-VT clinical trial and product design optimization program.

Adagio Medical Holdings reports a net income of $3.6 million for the period from July 31, 2024 to September 30, 2024, following its business combination, but expresses concerns about its ability to continue as a going concern.

Adagio Medical Holdings, Inc. reported recurring net losses and a going concern warning, despite advancing its vCLAS Cryoablation System with Breakthrough Device Designation and positive clinical trial results.

Adagio Medical Holdings files an amendment to its annual report to include information on directors, executive officers, corporate governance, and updated exhibits.

Adagio Medical Holdings files its 10-K, detailing 2024 financials, a strategic shift towards ventricular tachycardia treatment, and ongoing efforts to secure regulatory approvals.

Sean Salmon, a Director of Adagio Medical Holdings, Inc., received 30,000 shares of common stock on June 16, 2026.

Keyvan Mirsaeedi-Farahani, a Director of Adagio Medical Holdings, Inc., received 30,000 shares of common stock on June 16, 2026.

James L Cox, a Director of Adagio Medical Holdings, Inc., received 30,000 shares of common stock on June 16, 2026.

Sandra A. Gardiner, a Director of Adagio Medical Holdings, Inc., received 30,000 shares of common stock on June 16, 2026.

Orly Mishan, a Director of Adagio Medical Holdings, Inc., received 100,000 shares of common stock on June 16, 2026.

Timothy P. Moran, a Director of Adagio Medical Holdings, Inc., received 30,000 shares of common stock on June 16, 2026.

Adagio Medical Holdings, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 16, 2026.

Adagio Medical Holdings, Inc. announced the appointment of Sean Salmon, former Medtronic EVP, as a Class II independent director to its Board, Audit, and Compensation Committees.

Adagio Medical Holdings, Inc. announces its 2025 Annual Meeting of Stockholders to elect directors and ratify its independent accounting firm, while addressing recent capital raises and governance changes.

Adagio Medical Holdings updates its S-1 registration statement to facilitate the resale of up to 67,963,695 shares of common stock by selling stockholders.

Adagio Medical Holdings updates its S-1 registration statement to reflect executive compensation for the fiscal year ended December 31, 2024, with no additional securities being registered.

Adagio Medical Holdings seeks to register the resale of up to 67.9 million common shares by existing stockholders, including shares from PIPE investors, convertible noteholders, and the Sponsor.

Adagio Medical Holdings seeks to register the resale of shares by selling stockholders following its recent business combination, involving convertible notes and warrants.

Adagio Medical Holdings files for potential sale of up to 8,505,387 shares of common stock through a preliminary prospectus.

Adagio Medical Holdings seeks to register the resale of up to 32.9 million shares of its common stock by existing stockholders.

Sio Capital Management, LLC has reported a 3.15% ownership stake in Adagio Medical Holdings, Inc. as of June 30, 2026.

Perceptive Advisors and Joseph Edelman have filed an amendment reporting a 55.4% beneficial ownership stake in Adagio Medical Holdings, Inc.

Adage Capital Management, L.P. and its affiliates have increased their beneficial ownership of Adagio Medical Holdings, Inc. common stock to 5.67%.

Sio Capital Management, LLC has reported a 6.08% beneficial ownership stake in Adagio Medical Holdings, Inc. as of December 31, 2025.

Adage Capital Management, L.P. and its principals reported a 6.88% beneficial ownership stake in Adagio Medical Holdings, Inc. as of September 30, 2025.

RA Capital Management, L.P. and its affiliates filed an amended Schedule 13G to correct a clerical error, reporting a 7.2% beneficial ownership stake in Adagio Medical Holdings, Inc. as of June 30, 2025.